These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8627865)

  • 21. Hydroxyflutamide may not always be a pure antiandrogen.
    Yeh S; Miyamoto H; Chang C
    Lancet; 1997 Mar; 349(9055):852-3. PubMed ID: 9121269
    [No Abstract]   [Full Text] [Related]  

  • 22. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?
    Mottet N; Lucas C; Sene E; Avances C; Maubach L; Wolff JM
    Urol Int; 2005; 75(3):204-8. PubMed ID: 16215305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
    J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
    Herrada J; Dieringer P; Logothetis CJ
    J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Radical prostatectomy with broadened scope of indications - analysis of early experience].
    Chakarov S; Bechev R; Lazarov Z; Fachikov Ts; Rangelov S
    Khirurgiia (Sofiia); 1999; 55(3):47-8. PubMed ID: 11194670
    [No Abstract]   [Full Text] [Related]  

  • 26. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
    Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
    N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How early is early: androgen deprivation for prostate-specific antigen relapse in prostate cancer.
    Duchesne GM; Syme R; Howell D
    J Clin Oncol; 2006 Jun; 24(18):2964; author reply 2965. PubMed ID: 16782936
    [No Abstract]   [Full Text] [Related]  

  • 28. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
    Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
    J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer.
    deKernion JB
    J Urol; 1996 Jan; 155(1):226-7. PubMed ID: 7490840
    [No Abstract]   [Full Text] [Related]  

  • 30. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
    Scher HI; Kelly WK
    J Clin Oncol; 1993 Aug; 11(8):1566-72. PubMed ID: 7687666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen blockade in prostate cancer.
    Labrie F; Candas B
    Lancet; 2000 Jul; 356(9226):341-2. PubMed ID: 11071217
    [No Abstract]   [Full Text] [Related]  

  • 32. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM; Rose AL; Higano C
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.
    Middleman MN; Lush RM; Figg WD
    Pharmacotherapy; 1996; 16(3):376-81. PubMed ID: 8726595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate.
    Burch PA; Loprinzi CL
    J Clin Oncol; 1999 Mar; 17(3):1087-8. PubMed ID: 10071307
    [No Abstract]   [Full Text] [Related]  

  • 35. [Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
    Takada T; Ishizuya Y; Okada T; Ueda T; Inoue H; Hara T
    Hinyokika Kiyo; 2011 Jun; 57(6):291-5. PubMed ID: 21795830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re: Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
    Neulander EZ
    J Urol; 2004 Feb; 171(2 Pt 1):809; author reply 809-10. PubMed ID: 14713828
    [No Abstract]   [Full Text] [Related]  

  • 37. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract]   [Full Text] [Related]  

  • 38. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.
    Spry NA; Kristjanson L; Hooton B; Hayden L; Neerhut G; Gurney H; Corica T; Korbel E; Weinstein S; McCaul K
    Eur J Cancer; 2006 May; 42(8):1083-92. PubMed ID: 16632343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of androgen deprivation therapy on volume of anatomic zones of prostate in patients with prostate cancer using magnetic resonance imaging.
    Nishiyama T; Tomita Y; Takahashi K
    Urology; 2004 May; 63(5):917-21. PubMed ID: 15134981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer.
    Furuya Y; Nagakawa O; Fuse H
    Urol Int; 2003; 70(3):195-9. PubMed ID: 12660456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.